Core Viewpoint - Bright Minds Biosciences Inc. successfully closed a public offering of 1,945,000 common shares at a price of US$90.00 per share, raising gross proceeds of US$175,050,000 to fund clinical trials and research initiatives [1][2]. Group 1: Offering Details - The public offering consisted of 1,945,000 common shares priced at US$90.00 each, resulting in gross proceeds of US$175,050,000 [1]. - Underwriters were granted a 30-day option to purchase an additional 291,750 common shares at the public offering price [1]. - Jefferies, TD Cowen, Piper Sandler & Co., and Cantor acted as joint book-running managers for the offering [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized to fund future clinical trials for drug candidates targeting absence seizures, DEE, and Prader-Willi Syndrome [2]. - The company plans to initiate phase 1 clinical trials for BMB-105 and conduct additional research and development on earlier phase programs [2]. - Proceeds will also support general corporate and working capital purposes [2]. Group 3: Company Overview - Bright Minds is a biotechnology company focused on developing innovative treatments for neurological and psychiatric disorders [5]. - The company’s pipeline includes novel compounds targeting key receptors in the brain to address conditions with high unmet medical needs, such as epilepsy and depression [5]. - Bright Minds has developed a unique platform of highly selective serotonergic agonists, providing a rich portfolio of new chemical entity programs within neurology and psychiatry [6].

Core Viewpoint - Bright Minds Biosciences Inc. has announced a public offering of 1,945,000 common shares at a price of $90.00 per share, aiming for gross proceeds of $175,050,000 to fund clinical trials and research initiatives [1][3]. Group 1: Offering Details - The public offering consists of 1,945,000 common shares priced at $90.00 each, with expected gross proceeds of $175,050,000 [1]. - The underwriters have a 30-day option to purchase an additional 291,750 common shares at the public offering price [1]. - The closing of the offering is anticipated on January 9, 2026, pending customary closing conditions [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized to fund future clinical trials for drug candidates targeting absence seizures, developmental and epileptic encephalopathies (DEE), and Prader-Willi Syndrome [3]. - The funds will also support the initiation of phase 1 clinical trials for BMB-105 and additional research and development for earlier phase programs, along with general corporate and working capital purposes [3]. Group 3: Regulatory and Compliance - The company has filed a shelf registration statement on Form F-3 with the U.S. Securities and Exchange Commission (SEC), which became effective on September 2, 2025 [4]. - The offering is being conducted solely through a prospectus and a prospectus supplement that are part of the registration statement [4]. Group 4: Company Overview - Bright Minds is a biotechnology company focused on developing innovative treatments for neurological and psychiatric disorders, with a pipeline that includes novel compounds targeting key brain receptors [7]. - The company aims to deliver breakthrough therapies for conditions with high unmet medical needs, including epilepsy and depression [7][8].

Core Viewpoint - Bright Minds Biosciences Inc. has announced a public offering of 1,945,000 common shares at a price of $90.00 per share, aiming for gross proceeds of $175,050,000 to fund clinical trials and research initiatives [1][3]. Group 1: Offering Details - The offering includes a 30-day option for underwriters to purchase an additional 291,750 common shares at the public offering price [1]. - The closing of the offering is expected on January 9, 2026, pending customary closing conditions [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be allocated to fund future clinical trials for drug candidates targeting absence seizures, DEE, and Prader-Willi Syndrome, as well as initiating phase 1 clinical trials for BMB-105 and additional R&D for earlier phase programs [3]. Group 3: Company Background - Bright Minds is a biotechnology company focused on developing innovative treatments for neurological and psychiatric disorders, with a pipeline that includes novel compounds targeting key brain receptors [7]. - The company has developed a unique platform of highly selective serotonergic agonists, contributing to a rich portfolio of new chemical entity programs within neurology and psychiatry [8].

Core Insights - Bright Minds Biosciences is focused on developing innovative treatments for epilepsy disorders, specifically through its product BMB-101 [2] Company Overview - Bright Minds Biosciences is involved in the biotechnology sector, aiming to create long-term value in healthcare through its research and development efforts [2] - The company is part of a broader investment analysis service, Biotech Analysis Central, which provides extensive resources for investors in the biotech field [2] Investment Analysis - The Biotech Analysis Central service includes a library of over 600 biotech investing articles and a model portfolio featuring more than 10 small and mid-cap stocks, offering deep analysis for each [2]

Core Viewpoint - Bright Minds Biosciences Inc. is launching a public offering of common shares and pre-funded warrants to raise aggregate gross proceeds of US$100 million to fund clinical trials and research initiatives [1][2]. Group 1: Offering Details - The public offering includes common shares and pre-funded warrants, with a total gross proceeds target of US$100 million [1]. - The company will grant underwriters a 30-day option to purchase up to an additional 15% of the common shares issued in the offering [1]. - The offering is being conducted under a shelf registration statement that was declared effective by the SEC on September 2, 2025 [3]. Group 2: Use of Proceeds - Net proceeds from the offering will be used to fund future clinical trials for drug candidates targeting absence seizures, DEE, and Prader-Willi Syndrome [2]. - The funds will also support the initiation of phase 1 clinical trials for BMB-105 and additional research and development for earlier phase programs [2]. Group 3: Company Overview - Bright Minds is a biotechnology company focused on developing innovative treatments for neurological and psychiatric disorders [5]. - The company has a pipeline that includes novel compounds targeting key receptors in the brain to address conditions with high unmet medical needs, such as epilepsy and depression [5][6]. - Bright Minds has developed a unique platform of highly selective serotonergic agonists, contributing to a rich portfolio of new chemical entity programs within neurology and psychiatry [6].

Core Insights - Bright Minds Biosciences Inc. (NASDAQ:DRUG) stock is experiencing a significant increase following the positive topline results from its Phase 2 BREAKTHROUGH trial of BMB-101 for drug-resistant Absence Seizures and Developmental and Encephalopathic Epilepsies (DEE) [1][2]. Efficacy Results - The study met its primary efficacy endpoints in both cohorts, showing a robust reduction in seizures with a favorable safety profile [2]. - Absence Seizure Cohort (n=11) demonstrated a 73.1% median reduction in the number of absence seizures lasting ≥3 seconds (p = 0.012) and a 74.4% median reduction in total seizure time during 24 hours (p = 0.012) [3]. - DEE Cohort (n=6) showed a 63.3% median reduction in major motor seizures, with a 60.3% reduction in LGS patients and a 76.1% reduction in other DEE patients [4]. Safety Profile - BMB-101 was generally well tolerated, with 79.6% of treatment-emergent adverse events classified as mild and 17.2% as moderate, and no serious treatment-related adverse events reported [4]. Additional Effects - The study also noted a 90% increase in REM sleep duration (from 56.2 minutes at baseline to 106.7 minutes on BMB-101), while overall sleep duration remained stable [5]. Future Plans - Bright Minds Biosciences is preparing for global registrational trials in Absence Seizures and DEE, with additional data on long-term outcomes expected throughout the year [6]. - The company plans to initiate a study in Prader-Willi Syndrome, anticipated to start in Q1 2026 [6]. Stock Performance - Following the announcement, Bright Minds Biosciences stock rose by 22.23%, reaching $97.80 [6].

Group 1: Market Overview - U.S. stocks experienced an upward trend, with the Dow Jones index increasing by over 100 points on Tuesday [1] - Microchip Technology Inc's shares rose significantly after the company revised its fiscal third-quarter revenue expectations upward [1] Group 2: Microchip Technology Inc - Microchip now anticipates third-quarter fiscal 2026 net sales of approximately $1.185 billion, surpassing its previous guidance range of $1.109 billion to $1.149 billion [2] - The stock price of Microchip Technology increased by 8.1%, reaching $72.47 on Tuesday following the announcement [2] Group 3: Other Notable Stock Movements - Alumis Inc saw a remarkable 129% increase in its stock price to $19.04 after positive trial results for envudeucitinib [3] - Aeva Technologies Inc's stock rose by 31.5% to $17.21 due to its technology being selected for NVIDIA's autonomous vehicle platform [3] - Terrestrial Energy Inc's shares increased by 26.9% to $8.87 after securing an agreement with the U.S. Department of Energy [3] - Bright Minds Biosciences Inc gained 25% to $100.00 following successful Phase 2 trial results [3] - OneStream Inc's stock rose by 25.1% to $23.00 amid reports of a potential buyout [3] - Other companies such as SanDisk Corp, Beam Therapeutics Inc, and Albemarle Corp also recorded significant stock price increases [3]

Bright Minds Biosciences (NasdaqCM:DRUG) Update / Briefing January 06, 2026 08:00 AM ET Company ParticipantsJan Torleif Pedersen - Chief Scientific OfficerIan McDonald - CEOStephen Collins - Chief Medical OfficerIan McDonaldGood morning, and thank you for joining us. This is Ian McDonald, Chief Executive Officer of Bright Minds Biosciences. Today we're reporting the top-line data from the phase II breakthrough study of BMB-101 in adults with drug-resistant absence seizures, as well as developmental and epil ...

Core Insights - Bright Minds Biosciences announced positive topline results from its Phase 2 BREAKTHROUGH clinical trial for BMB-101, showing significant efficacy in reducing seizures in patients with drug-resistant Absence Seizures and Developmental and Encephalopathic Epilepsies [1] Study Overview - The Phase 2 study was an open-label, multicenter trial that evaluated the safety, tolerability, and efficacy of BMB-101 in adults, enrolling 24 patients, surpassing the target of 20 [2] - The study included a 4-week baseline period followed by a 4-week titration and maintenance period [2] Patient Profile - The study enrolled 24 patients, with 15 having Absence Seizures and 9 with DEE, with a mean age of 30 years [3] - Patients had a median of 3 concomitant anti-seizure treatments in the Absence cohort and 5 in the DEE cohort, having previously failed up to 16 treatments [3] Efficacy Results - BMB-101 demonstrated a 73.1% median reduction in Absence Seizures lasting ≥3 seconds (p = 0.012) and a 63.3% median reduction in major motor seizures in the DEE cohort [6][15] - The study also reported a 90% increase in REM sleep duration in patients with Absence Seizures, with no change in total sleep duration [11] Safety and Tolerability - BMB-101 was generally well tolerated, with 79.6% of treatment-emergent adverse events being mild and 17.2% moderate, with no serious treatment-related adverse events reported [10] - The most common adverse events included respiratory infections (20.8%), fatigue (16.7%), and constipation (16.7%) [10] Next Steps - Bright Minds has initiated preparations for global registrational trials in both Absence Seizures and DEE, with additional data on long-term outcomes expected throughout the year [12] - The company plans to initiate a study in Prader Willi Syndrome in Q1 2026 [12]

Core Insights - Several biotechnology and pharmaceutical companies experienced significant stock price increases in after-hours trading due to clinical trial updates, regulatory advancements, and investor anticipation for upcoming data releases [1] Company Updates - Alumis Inc. (ALMS) saw a surge of 17.33% to $9.75, gaining $1.44 after announcing that topline data from its Phase 3 ONWARD clinical program for envudeucitinib in moderate-to-severe plaque psoriasis will be reported on January 6, 2026, along with a conference call to discuss the results [2] - Genelux Corp. (GNLX) climbed 10.92% to $3.86, up $0.38, following interim results from ongoing trials evaluating Olvi-Vec in patients with progressive small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) [3] - Bright Minds Biosciences Inc. (DRUG) rose 8.42% to $86.75, gaining $6.74, and announced a conference call on January 6, 2026, to report topline results from its Phase 2 trial of BMB-101 in patients with drug-resistant Absence Seizures [4] - Context Therapeutics Inc. (CNTX) shares increased by 8.36% to $1.68, adding $0.13, despite no specific news released [4] - BioAtla, Inc. (BCAB) gained 3.95% to $0.44, up $0.017, after announcing a special purpose vehicle transaction to advance ozuriftamab vedotin in a Phase 3 study for oropharyngeal squamous cell carcinoma, receiving $5 million in initial funding [5] - Femasys Inc. (FEMY) added 7.09% to $0.6223, up $0.04, with no new updates reported [5] - Acumen Pharmaceuticals, Inc. (ABOS) jumped 11.62% to $2.21, gaining $0.23, also without new corporate updates [6] - Alpha Tau Medical Ltd. (DRTS) rose 5.36% to $5.50, up $0.28, after submitting the first module of its pre-market approval application to the FDA for Alpha DaRT in treating recurrent cutaneous squamous cell carcinoma [7]